Investigating gut bacteria changes during stem cell transplant
Intestinal Microbiota Alteration by Antibiotics Used During Stem Cell Transplant Admission
This study is trying to see how antibiotics used during stem cell transplants affect gut bacteria and whether these changes influence complications like graft-versus-host disease and relapse rates in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 255 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Henry Ford Health System Academic / other |
| Locations | 1 site (Detroit, Michigan) |
| Trial ID | NCT04623424 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore how antibiotic use during stem cell transplant admissions affects the composition of intestinal microbiota over time. By collecting stool samples from patients at various stages of the transplant process, researchers will analyze the relationship between antibiotic regimens and changes in gut bacteria. The study focuses on understanding the potential impact of these changes on complications such as acute graft-versus-host disease (aGVHD) and relapse rates. This research could provide insights into optimizing antibiotic use to improve transplant outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 18-80 undergoing allogenic or autologous stem cell transplants for malignant hematological conditions or bone marrow failure.
Not a fit: Patients who are not undergoing stem cell transplants or those outside the age range of 18-80 may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of antibiotic use during stem cell transplants, potentially reducing complications and enhancing patient recovery.
How similar studies have performed: While there is emerging evidence regarding the impact of intestinal microbiota on transplant outcomes, this specific approach to studying antibiotic effects on microbiota during stem cell transplants is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18-80 years * patients undergoing allogenic or autologous SCT for malignant hematological conditions or bone marrow failure
Where this trial is running
Detroit, Michigan
- Henry Ford Health System — Detroit, Michigan, United States (Recruiting)
Study contacts
- Principal investigator: shatha farhan — Henry Ford
- Study coordinator: shatha farhan, MD
- Email: SFARHAN1@HFHS.ORG
- Phone: 313 916 5002
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.